About Alliance Pharma (LON:APH)
Alliance Pharma plc operates as a specialty pharmaceutical company in Europe and internationally. It acquires the rights to established products, and owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The company provides prescription only medicines, over the counter medications, cosmetics, and nutritional supplements, as well as medical devices. It offers products in various therapeutic areas, including acquired healthcare, cardiovascular, central nervous system, child health, consumer health, dermatology, endocrinology, gastroenterology, obstetrics and gynecology, oral health, oncology, stoma care, toxicology, travel health, urology, vitamins and minerals, and others. The company distributes its products through pharmacies, supermarkets, healthcare distributors, and retailers, as well as online retailers. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
Industry, Sector and Symbol
Industry Drugs - Generic
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity14.63%
Return on Assets8.39%
Alliance Pharma (LON:APH) Frequently Asked Questions
What is Alliance Pharma's stock symbol?
Alliance Pharma trades on the London Stock Exchange (LON) under the ticker symbol "APH."
How often does Alliance Pharma pay dividends? What is the dividend yield for Alliance Pharma?
Alliance Pharma announced a dividend on Tuesday, March 27th. Investors of record on Thursday, June 14th will be given a dividend of GBX 0.89 per share on Wednesday, July 11th. This represents a yield of 1.3%. The ex-dividend date is Thursday, June 14th. This is a positive change from Alliance Pharma's previous dividend of $0.44. The official announcement can be accessed at this link. View Alliance Pharma's Dividend History.
What price target have analysts set for APH?
3 equities research analysts have issued 12-month target prices for Alliance Pharma's stock. Their forecasts range from GBX 59 to GBX 88. On average, they anticipate Alliance Pharma's share price to reach GBX 72.33 in the next twelve months. View Analyst Ratings for Alliance Pharma.
Who are some of Alliance Pharma's key competitors?
Some companies that are related to Alliance Pharma include Myovant Sciences (MYOV), G1 Therapeutics (GTHX), REGENXBIO (RGNX), Brookdale Senior Living (BKD), Intersect ENT (XENT), Cellectis (CLLS), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), PTC Therapeutics (PTCT), Natus Medical (BABY), Mallinckrodt (MNK) and Mayne Pharma Group (MYX).
Who are Alliance Pharma's key executives?
Alliance Pharma's management team includes the folowing people:
- Mr. John Dawson, Founder, CEO & Exec. Director (Age 69)
- Mr. Andrew Timothy Franklin, CFO & Exec. Director (Age 52)
- Mr. Peter Jonathan Butterfield, Deputy CEO & Exec. Director (Age 42)
- Mr. Stephen Kidner, Chief Scientific & Operations Officer
- Mr. Daniel Thomas, Chief Corp. Devel. Officer
Has Alliance Pharma been receiving favorable news coverage?
Media coverage about APH stock has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alliance Pharma earned a daily sentiment score of 0.22 on Accern's scale. They also gave news coverage about the company an impact score of 48.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Alliance Pharma?
Shares of APH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Alliance Pharma's stock price today?
One share of APH stock can currently be purchased for approximately GBX 78.20.
How big of a company is Alliance Pharma?
Alliance Pharma has a market capitalization of £323.02 million.
How can I contact Alliance Pharma?
Alliance Pharma's mailing address is Avonbridge House, Bath Road, CHIPPENHAM, SN15 2BB, United Kingdom. The company can be reached via phone at +44-1249-466966.
MarketBeat Community Rating for Alliance Pharma (APH)MarketBeat's community ratings are surveys of what our community members think about Alliance Pharma and other stocks. Vote "Outperform" if you believe APH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alliance Pharma (LON:APH) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Alliance Pharma (LON APH) Insider Trading and Institutional Ownership History
Alliance Pharma (LON APH) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/14/2017||Peter Butterfield||Insider||Sell||61,846||GBX 49||£30,304.54|
|9/22/2016||John Dawson||Insider||Sell||3,000,000||GBX 45||£1,350,000|
|12/17/2015||Smith,Andrew L||Insider||Buy||75,000||GBX 41||£30,750|
|6/16/2015||Nigel Clifford||Insider||Buy||58,227||GBX 39.50||£22,999.67|
Alliance Pharma (LON APH) News Headlines
Alliance Pharma (LON:APH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Alliance Pharma (LON APH) Stock Chart for Tuesday, April, 24, 2018